

## **SUPPLEMENTARY MATERIAL-2**

### ***Ex vivo* cytokine responses of PBMC upon stimulation with recombinant HMGB1 and LAM**

#### **(1) HMGB1 alone, active PTB patients vs asymptomatic individuals**

[results are expressed as percentage of subjects showing a positive response, ie, fold-change >1.0]:

TNF- $\alpha$ , 44.3% vs 28.9% (P=0.090)

IL-18, 57.0% vs 33.3% (P=0.011)\*

IL-10, 11.4% vs 8.9% (P>0.05)

IL-6, 48.1% vs 53.3% (P>0.05)

IL-8/CXCL8, 22.8% vs 26.7% (P>0.05)

#### **(2) HMGB1+LAM, active PTB patients vs asymptomatic individuals**

[results are expressed as fold-change in cytokine release, median(IQR)]:

TNF- $\alpha$ , 14.4 (4.7-39.9) vs 6.1 (2.8-11.0) pg/mL (P=0.001)\*

IL-18, 1.0 (1.0-1.2) vs 1.0 (1.1-1.3) pg/mL (P>0.05)

IL-10, 1.0 (1.0-3.7) vs 1.0 (1.0-1.0) pg/mL (P=0.006)\*

IL-6, 102.2 (22.4-261.0) vs 58.3 (24.1-150.3) pg/mL (P>0.05)

IL-8/CXCL8, 1.0 (1.0-1.0) vs 1.0 (1.0-1.8) pg/mL; 95<sup>th</sup> percentile 518.0 vs 12.2 pg/mL (P>0.05)

[The magnitude of fold-change was compared as most subjects showed a cytokine concentration ratio >1.0, e.g. TNF- $\alpha$ , IL-6]